Switch theme
Sign up to access all valuation multiples
Bluelinea SA is engaged in designing and developing of electronic surveillance and medical teleassistance systems.
2014
45
LTM Revenue n/a
LTM EBITDA n/a
$12.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bluelinea has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Bluelinea achieved revenue of $10.6M and an EBITDA of $20K.
Bluelinea expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bluelinea valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $11.2M | $10.6M | XXX | XXX | XXX |
| Gross Profit | $1.5M | $7.1M | XXX | XXX | XXX |
| Gross Margin | 13% | 67% | XXX | XXX | XXX |
| EBITDA | $0.2M | $20K | XXX | XXX | XXX |
| EBITDA Margin | 1% | 0% | XXX | XXX | XXX |
| Net Profit | -$3.3M | -$1.7M | XXX | XXX | XXX |
| Net Margin | -30% | -16% | XXX | XXX | XXX |
| Net Debt | $3.8M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Bluelinea's stock price is EUR 1 (or $1).
Bluelinea has current market cap of EUR 7.7M (or $8.3M), and EV of EUR 11.4M (or $12.2M).
See Bluelinea trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.2M | $8.3M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Bluelinea has market cap of $8.3M and EV of $12.2M.
Bluelinea's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Bluelinea's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Bluelinea and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $12.2M | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | 610.6x | XXX | XXX | XXX |
| P/E | -4.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -3.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBluelinea's NTM/LTM revenue growth is n/a
Bluelinea's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Bluelinea's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Bluelinea's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Bluelinea and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -5% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 0% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -87% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 77% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bluelinea acquired XXX companies to date.
Last acquisition by Bluelinea was XXXXXXXX, XXXXX XXXXX XXXXXX . Bluelinea acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Bluelinea founded? | Bluelinea was founded in 2014. |
| Where is Bluelinea headquartered? | Bluelinea is headquartered in France. |
| How many employees does Bluelinea have? | As of today, Bluelinea has 45 employees. |
| Is Bluelinea publicy listed? | Yes, Bluelinea is a public company listed on PAR. |
| What is the stock symbol of Bluelinea? | Bluelinea trades under ALBLU ticker. |
| When did Bluelinea go public? | Bluelinea went public in 2012. |
| Who are competitors of Bluelinea? | Similar companies to Bluelinea include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Bluelinea? | Bluelinea's current market cap is $8.3M |
| What is the current revenue growth of Bluelinea? | Bluelinea revenue growth between 2023 and 2024 was -5%. |
| Is Bluelinea profitable? | Yes, Bluelinea is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
